6-109146758-C-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_001271852.3(CEP57L1):āc.161C>Gā(p.Ala54Gly) variant causes a missense, splice region change. The variant was absent in control chromosomes in GnomAD project. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: not found (cov: 32)
Exomes š: 7.2e-7 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
CEP57L1
NM_001271852.3 missense, splice_region
NM_001271852.3 missense, splice_region
Scores
1
12
6
Splicing: ADA: 0.6669
2
Clinical Significance
Conservation
PhyloP100: 5.43
Genes affected
CEP57L1 (HGNC:21561): (centrosomal protein 57 like 1) Enables identical protein binding activity. Predicted to be located in cytoplasm and microtubule. Predicted to be active in centrosome. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CEP57L1 | NM_001271852.3 | c.161C>G | p.Ala54Gly | missense_variant, splice_region_variant | 3/11 | ENST00000517392.6 | NP_001258781.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CEP57L1 | ENST00000517392.6 | c.161C>G | p.Ala54Gly | missense_variant, splice_region_variant | 3/11 | 2 | NM_001271852.3 | ENSP00000427844 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD3 exomes AF: 0.00000529 AC: 1AN: 188998Hom.: 0 AF XY: 0.00000963 AC XY: 1AN XY: 103880
GnomAD3 exomes
AF:
AC:
1
AN:
188998
Hom.:
AF XY:
AC XY:
1
AN XY:
103880
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 7.15e-7 AC: 1AN: 1398454Hom.: 0 Cov.: 29 AF XY: 0.00000144 AC XY: 1AN XY: 694024
GnomAD4 exome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
1
AN:
1398454
Hom.:
Cov.:
29
AF XY:
AC XY:
1
AN XY:
694024
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
Alfa
AF:
Hom.:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 16, 2024 | The c.161C>G (p.A54G) alteration is located in exon 5 (coding exon 2) of the CEP57L1 gene. This alteration results from a C to G substitution at nucleotide position 161, causing the alanine (A) at amino acid position 54 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T;T;T;T;.;T;T;T;T;.;T;T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;.;D;D;D;D;D;D;D;.;D;D;D;D
M_CAP
Benign
D
MetaRNN
Uncertain
T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;M;.;.;.;.;.;.;.;.;M;.;.;M
MutationTaster
Benign
D;D;D;D;D;D;D;D;D;D
PrimateAI
Benign
T
PROVEAN
Uncertain
D;D;D;D;D;D;D;D;D;D;D;D;D;D
REVEL
Benign
Sift
Uncertain
D;D;D;D;D;D;D;D;D;D;D;D;D;D
Sift4G
Uncertain
D;D;D;D;D;D;D;T;T;D;D;D;D;D
Polyphen
D;D;D;.;.;.;.;.;.;D;.;.;.;D
Vest4
MutPred
Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);Gain of catalytic residue at P50 (P = 0.0696);.;Gain of catalytic residue at P50 (P = 0.0696);
MVP
MPC
0.30
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
dbscSNV1_RF
Benign
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at